Our RESETTM clinical trials with rese-cel (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 10/30/19 | 8-K | Current report filing |
|
34 | |
| 10/30/19 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 10/30/19 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 10/29/19 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans |
|
9 | |
| 10/29/19 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 10/28/19 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 10/28/19 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 10/28/19 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 10/28/19 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 10/25/19 | 424B4 | Prospectus filed pursuant to Rule 424(b)(4) |
|
245 |
